Acadia Pharmaceuticals and Biovail announced the completion of enrollment in the first Phase 3 trial of pimavanserin in patients with Parkinson’s disease psychosis (PDP). This trial enrolled 298 patients in a multi-center, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of pimavanserin in patients with PDP.  The primary endpoint of this and a second Phase 3 trial is antipsychotic efficacy as measured using the Scale for the Assessment of Positive Symptoms, or SAPS. A secondary endpoint is motoric tolerability as measured using the Unified Parkinson’s Disease Rating Scale, or UPDRS (Parts II and III).

Pimavanserin is a 5-HT2A receptor inverse agonist in development as a once-daily oral tablet.  

For more information call (858) 558-2871 or visit